{"nctId":"NCT01280266","briefTitle":"Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon","startDateStruct":{"date":"2011-01"},"conditions":["Raynaud Phenomenon"],"count":29,"armGroups":[{"label":"Amlodipine-Udenafil (AU) arm","type":"EXPERIMENTAL","interventionNames":["Drug: Udenafil or Amlodipine"]},{"label":"Udenafil-Amlodipine (UA) arm","type":"EXPERIMENTAL","interventionNames":["Drug: Udenafil or Amlodipine"]}],"interventions":[{"name":"Udenafil or Amlodipine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* secondary Raynaud's phenomenon\n\nExclusion Criteria:\n\n* primary raynaud phenomenon\n* active infection\n* hypersensitivity to PDE5 inhibitor or Calcium Chanel Blocker (CCB)\n* elevated AST/ALT (3 times above the upper normal limit)\n* severe renal failure\n* patients on nitrite or nitric oxide (NO) donor treatment\n* recent history of cerebrovascular accidents, acute myocardial infarction, or coronary artery bypass surgery\n* hypotension (less than 90/50 mmHg) or uncontrolled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"RP Attacks Per Day","description":"Change in RP frequency after amlodipine and udenafil number of RP attack per day 0 -- unlimited.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.4"},{"groupId":"OG001","value":"-0.5","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change in Raynaud's Condition Score (RCS)","description":"change in the RCS. RCS combines daily activty, frequency, duration and severity as well as impact of RP attack (Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Merkel et al,Arthritis Rheum. 2002 Sep;46(9):2410-20).\n\nRange 0-10 ordinal scale 0..good 10.. bad","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.5"},{"groupId":"OG001","value":"-0.3","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change in the RP Duration","description":"Change in the average RP duration in minutes (min) per attack. 0 -- unlimited","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"5.9"},{"groupId":"OG001","value":"-1.4","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Change in Health Assessment Questionnaire (HAQ)","description":"Ordinal scale 0-10 0 good 10 bad","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.4"},{"groupId":"OG001","value":"-0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Physician's Global Assessment on Visual Analogue Scale (VAS)","description":"Physician's global assessment (PGA) on VAS assesses the overall condition of the patient. The scale ranges from 0 - 10, with 0 being good and 10 bad. As such, change in the GPA measures the change in the patient's condition from the baseline.\n\nnegative value (decrease in value) means improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.4"},{"groupId":"OG001","value":"-1.5","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Change in Digital Ulcer Number","description":"0 - unlimited. Number of digital ulcers in all fingers are counted by the investigators and recorded at each visit. The number of ulcers in all fingers indirectly reflect the extent of critical ischemia. As such. the decrease in digital ulcer number reflects positive response to treatment (=better blood flow), whereas the increase ulcer numbers indicates worsening finger ischemia from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.4"},{"groupId":"OG001","value":"0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Peak Systolic Flow (cm/Sec)","description":"Change in digital artery flow velocity in proper palmar digital artery in cm/sec.\n\n0-unlimited","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.9","spread":"145.9"},{"groupId":"OG001","value":"63.2","spread":"170.2"}]}]}]},{"type":"SECONDARY","title":"Time-averaged Peak Velocity (cm/Sec)","description":"changes in the averaged blood flow (Time-averaged peak velocity) Blood flow in cm/sec 0 - unlimited.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.3","spread":"98.6"},{"groupId":"OG001","value":"33.4","spread":"123"}]}]}]},{"type":"SECONDARY","title":"Dorsal-digital-difference.","description":"The temperature difference between finger tips and dorsum of same hand. range 0 - unlimited in degree celcius.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"3.2"},{"groupId":"OG001","value":"-1.4","spread":"3.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Facial flushing","Facial edema","Peripheral edema","Headache","Blurred vision"]}}}